Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours - Nature
Briefly

"GDF-15 is a prominent molecule used by tumours to keep the immune system at bay, mirroring its physiological role in feto-maternal tolerance towards placental alloantigens."
"The GDFATHER clinical trial of the GDF-15-blocking antibody visugromab showed promising results, combining it with anti-PD-1 to enhance the treatment of relapsed or refractory cancer patients."
Read at Nature
[
|
]